Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
出版年份 2020 全文链接
标题
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001191
出版商
BMJ
发表日期
2020-10-21
DOI
10.1136/jitc-2020-001191
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA
- (2020) Christopher J. Holland et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
- (2020) Christianne Groeneveldt et al. TRENDS IN IMMUNOLOGY
- T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
- (2019) Lin Yu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
- (2018) Tobias Speck et al. CLINICAL CANCER RESEARCH
- MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection
- (2018) Dmitri V. Rozanov et al. Journal of Proteomics
- Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
- (2018) Danielle Mandikian et al. MOLECULAR CANCER THERAPEUTICS
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
- (2018) Adel Samson et al. Science Translational Medicine
- A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- (2018) Devalingam Mahalingam et al. Cancers
- Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
- (2018) Karie Runcie et al. MOLECULAR MEDICINE
- Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
- (2018) Robert A. Berkeley et al. Cancer Immunology Research
- CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory
- (2018) Hreinn Benonisson et al. MOLECULAR CANCER THERAPEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- (2016) N. Haense et al. BMC CANCER
- Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus
- (2016) X. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Viral gene expression potentiates reovirus-induced necrosis
- (2015) Bradley E. Hiller et al. VIROLOGY
- A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
- (2014) D. W. Sborov et al. CLINICAL CANCER RESEARCH
- Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates
- (2014) Delphine Goubau et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Sensitive and Specific Quantitative Detection of Rotavirus A by One-Step Real-Time Reverse Transcription-PCR Assay without Antecedent Double-Stranded-RNA Denaturation
- (2013) S. Mijatovic-Rustempasic et al. JOURNAL OF CLINICAL MICROBIOLOGY
- T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
- (2013) Feng Yu et al. MOLECULAR THERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-A
- (2012) Diana J. M. van den Wollenberg et al. PLoS One
- A New Mouse Model for the Study of Human Breast Cancer Metastasis
- (2012) Elizabeth Iorns et al. PLoS One
- Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
- (2012) R. A. Adair et al. Science Translational Medicine
- Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
- (2010) C. M. Thirukkumaran et al. CANCER RESEARCH
- Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
- (2010) K.J. Harrington et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Induction of type I interferon by RNA viruses: cellular receptors and their substrates
- (2009) Alina Baum et al. AMINO ACIDS
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity
- (2009) E J Ilett et al. GENE THERAPY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started